Patent classifications
A61K49/18
Cellular targeted label delivery system
The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and/or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.
TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR
Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3). Also disclosed are conjugates and compositions that include the peptides and/or peptidomimetics, methods for directing a moiety to tumor lymphatic vasculature, methods for imaging tumor lymphatic vasculature, methods for reducing or inhibiting tumor metastasis, methods for reducing the number of tumor lymphatic vessels, methods for treating cancer, methods for treating a disease or disorder associated with a gC1q/p32 receptor biological activity, methods for detecting the presence of a gC1q/p32 receptor, methods for detecting interactions between gC1q/p32 receptors and the presently disclosed conjugates and compositions, methods for delivering the presently disclosed conjugates and compositions to gC1q/p32 receptors, methods for assessing gC1q/p32 receptor levels in cells, methods for identifying subjects having diseases associated with gC1q/p32 receptor biological activities, and methods for screening for compounds that interact with gC1q/p32 receptors.
Mapping glutathione deficiency and/or dysfunction of mitochondria
The disclosed invention is a method for mapping glutathione deficiency and/or mitochondria dysfunction in disease states, utilizing glutathione and its precursors as imaging tracers in conjunction with medical imaging techniques, particularly magnetic resonance imaging. The innovation involves administering glutathione or glutathione-increasing interventions, such as oral liposomal reduced glutathione, to enhance imaging accuracy. The proposed methodology aims to identify and monitor regions of depleted reduced glutathione (GSH) in various organs and tissues. The maps generated through this process provide valuable biomarkers for toxic exposure, early biological effects, and health risks. The approach is versatile, offering applications in mental health, neurological disorders, inflammation, organ dysfunction, and personalized treatment and risk assessments.
MANUFACTURING AND APPLICATION OF MANGANESE-BASED THERANOSTIC NANOPARTICLE TECHNOLOGY
A method of manufacture and compositions and uses of a multifunctional bioinorganic theranostic nanoconstruct are disclosed. Nanoconstructs described herein contain manganese dioxide in a biocompatible matrix and are useful for, e.g., MRI contrast imaging of tumor environments and enhancement of radiation therapy in cancer. Some nanoconstructs described herein incorporate targeting agents for specific targeting of cancer cells.
Methods and systems for cell labeling and imaging
The present disclosure provides methods and systems for cell processing, including delivery of imaging agents into cells. The methods and systems may comprise the use of a microfluidic device. The microfluidic device may comprise a channel comprising a compressive element. The compressive element may be configured to reduce a volume of the cell and facilitate the formation of one or more transient pores in a cell membrane of the cell. The one or more pores may permit one or more imaging agents to enter the cell. Also provided are modified cells produced using the disclosed methods and systems and methods of imaging the modified cells in a subject.
DUAL T1/T2 MRI CONTRAST AGENTS FOR PHOTOTHERMAL THERAPY
A photothermal magnetic resonance imaging enhancement agent includes composite nanoparticles. The composite nanoparticle includes an inner layer of a dielectric material with a porous substrate having pores, an inner layer with a core, magnetically responsive nanoparticles disposed on the porous substrate, and an outer layer of a metallic material around the inner layer and the magnetically responsive nanoparticles. A method of making a photothermal magnetic resonance imaging enhancement agent includes synthesizing a dielectric substrate, baking the dielectric substrate to generate pores, synthesizing magnetically responsive nanoparticles, loading the magnetically responsive nanoparticles into the pores, attaching linker molecules to the dielectric core, attaching a metal nanoparticle to at least a portion of the linker molecules, reducing additional metal onto the metal nanoparticles to form an outer layer disposed on the dielectric inner layer, and selecting reducing a condition such that the outer layer has a controllable thickness forming a composite nanoparticle.
Method for increasing dispersion stability of nanoparticles as T1 MRI contrast agent and T1 MRI contrast nanoparticles
The present invention improves an existing contrast agent, especially, a T1 contrast agent, and adopts a strategy in which the T1 contrast material is partially coated on a support surface to which a hydrophilic functional group is exposed. The partial coating strategy adopted in the present invention improves both the stability and contrast performance of T1 contrast agent nanoparticles, and such a strategy leads to very interesting technical development.
Superparamagnetic particle imaging and its applications in quantitative multiplex stationary phase diagnostic assays
Superparamagnetic nanoparticle-based analytical method comprising providing a sample having analytes in a sample matrix, providing a point of care chip having analytical regions, each of which is a stationary phase having at least one or more sections, labeling each of the analytes with a superparamagnetic nanoparticle and immobilizing the labeled analytes in the stationary phase, providing an analytical device having a means for exciting the superparamagnetic nanoparticles in vitro and a means for sensing, receiving, and transmitting response of the excited superparamagnetic nanoparticles, placing the chip in the analytical device and exciting the superparamagnetic nanoparticles in vitro, sensing, receiving, and transmitting the response of the superparamagnetic nanoparticles, and analyzing the response and determining characteristic of the analytes, wherein the response of the superparamagnetic nanoparticles comprises harmonics. The present invention also provides the hybrid point of care chip and analyzer to be used in the analytical method.
Nanocarrier systems for imaging and delivery of active agents
Synthetic nanocarrier constructs and related compositions comprising a lipid-based bilayer membrane infused with one or more NK-92 cell membrane proteins, which encapsulates a liquid receiving interior space or coats at least a portion of a solid core. Methods of targeted delivery of an active/diagnostic/imaging agent to a specific cell type or a region of a patient by administering a plurality of nanocarrier constructs to the patient. MRI imaging methods and novel MRI contrast agent constructs are also disclosed.
COMPOSITIONS AND METHODS FOR DELIVERY OF RNA
The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.